Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2

摘要: Malignant melanoma of the uvea is remarkable for purely haematogenous dissemination and its tendency to metastasise liver. Although liver involved in up 95% patients, 50% these also develop extrahepatic metastases, most often lungs, bone, skin, brain. The only effective treatments reported date relied on hepatic arterial chemoembolisation or -perfusion. objective this study was establish a therapy protocol addressing patients with both sole involvement systemic disease. Forty-eight metastatic ocular received fotemustine 100 mg m−2 either as 60-min infusion into artery 15-min via peripheral vein, depending sites involved, i.e., restriction together For first treatment cycle repeated after one week. all cycles, subsequent three week resting period, an immunotherapy consisting subcutaneous interleukin 2 interferon α2. responses were more frequent within cohort receiving intraarterial (21.7 vs 8%), difference did not translate significant benefit overall survival, 369 349 days, respectively. Of note, survival much longer than that repeatedly stage IV uveal treated fotemustine, suggesting therapeutic activity cytostatic drug even administration.